Wegovy HD (7.2 mg): Cost, Results, and Who the Higher Dose Is For

Wegovy HD is the new higher-dose version of semaglutide, dosed at 7.2 mg once weekly, and it costs $399 a month as a self-pay cash price through NovoCare Pharmacy. The FDA approved it on March 19, 2026. In its main trial, patients lost about 20.7% of their body weight on average, with roughly one in three losing 25% or more. The key thing to understand: Wegovy HD isn’t a starting dose. It’s for people who’ve already been on the standard 2.4 mg dose for at least four weeks and need more weight reduction. If you’re new to semaglutide, you start lower and may step up to it later.

Here’s how the higher dose works, what it costs across every payment route, and how to tell whether it’s a fit.

What Wegovy HD is and how it’s different

Wegovy HD contains the same active ingredient as regular Wegovy: semaglutide. The difference is the dose. For years, 2.4 mg weekly was the ceiling for injectable semaglutide. Wegovy HD raises that ceiling to 7.2 mg, three times higher, for patients whose weight loss stalled before they reached their goal.

The approval came through a new FDA pathway called the Commissioner’s National Priority Voucher program, which accelerated the review. Wegovy HD launched in the US in April 2026 as a single-dose pen, taken once a week like the standard version. It’s worth knowing that the 7.2 mg dose was already approved in the UK and EU before the US cleared it.

The label is specific about sequencing. You qualify for Wegovy HD after you’ve tolerated the 2.4 mg dose for at least four weeks and your prescriber decides additional weight reduction is clinically warranted. It’s a step-up option, not a first prescription.

What the trial actually showed

Wegovy HD’s approval rested on the STEP UP trial, which enrolled about 1,400 adults with obesity and no diabetes over 72 weeks (Wharton et al., Lancet Diabetes & Endocrinology 2025). The headline figure, around 20.7% average weight loss, reflects results if everyone stayed on treatment. Measured across everyone regardless of whether they stuck with it, the average was closer to 18 to 19%. Either way, roughly one in three people on 7.2 mg lost at least a quarter of their body weight, compared with about 15% of those on the 2.4 mg dose.

For context, that pushes semaglitude into weight-loss territory that used to require the strongest injectables or surgery. The 2.4 mg dose in the same trial produced about 15 to 16%, so the higher dose adds a meaningful increment for people who’d plateaued.

The safety profile matched what’s already known about semaglutide. Gastrointestinal effects (nausea, diarrhea, vomiting, constipation) were the most common and showed up more often at the higher dose. Wegovy HD carries the same boxed warning for thyroid C-cell tumors and isn’t for anyone with a personal or family history of medullary thyroid cancer or MEN-2. As with any semaglutide product, you stop it two months before a planned pregnancy.

What Wegovy HD costs in 2026

The list price for Wegovy HD is $1,349.02 per package, the same sticker as the standard pen. Almost nobody should pay that. Here’s the real range.

The $399 NovoCare self-pay price is $50 more than the $349 charged for the standard Wegovy doses, reflecting the higher strength. If you have commercial insurance that covers Wegovy, the savings card route is cheaper, dropping the cost to as little as $25 a month. And eligible Medicare members can access all dose strengths, including 7.2 mg, for $50 a month through the Medicare GLP-1 Bridge once it opens.

Who should consider it, and who shouldn’t

Consider a scenario where someone has been on Wegovy 2.4 mg for eight months, lost about 12% of their body weight, and then watched the scale stall well short of their goal while tolerating the medication fine. That’s close to the textbook candidate for Wegovy HD: an established patient with room to lose more and no significant side-effect problems at the current dose.

It’s a poorer fit in a few situations. If you’re brand new to semaglutide, you can’t start here; you titrate up from 0.25 mg first. If you’re already getting strong results on 2.4 mg, there’s little reason to push higher. And if GI side effects are already hard to manage at your current dose, a stronger dose tends to amplify them rather than solve the problem.

For a broader look at how the injectable and pill forms of semaglutide stack up, our breakdown of whether Wegovy works better as a shot or a pill covers the tradeoffs, and our overview of what realistic results look like over time sets expectations for the full course.

The cash-pay alternative

Wegovy HD at $399 a month is a strong deal for the brand product if you specifically want branded semaglutide at the maximum dose and you don’t have coverage. The main alternative for cash-paying patients is a telehealth program built around the same molecule. Our guide to getting semaglutide for less walks through how those routes compare.

TrimRx is a cash-pay telehealth program that connects you with licensed providers for physician-prescribed semaglutide and tirzepatide, with monthly pricing across the program’s medications running from $179 to $1,579 depending on the medication and plan. It bundles the provider visit and shipping into a flat monthly structure with no insurance required. To see whether it fits your situation, the free assessment quiz takes a few minutes and routes your information to a licensed provider for review.

This article is for general educational purposes and isn’t medical advice. Wegovy HD is a step-up dose with specific eligibility requirements, carries a boxed warning, and isn’t appropriate for everyone. Drug pricing and programs change frequently, so verify current details with NovoCare, your insurer, and your prescriber before making decisions.